Literature DB >> 9307745

Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone.

G Leese1, R Jeffreys, J Vora.   

Abstract

A patient with a pituitary adenoma secreting follicle-stimulating hormone with co-existent primary hyperaldosteronism is described. After his second transsphenoidal surgery, the patient developed a Staphylococcus aureus pituitary abscess. Symptoms improved after abscess drainage. Subsequent cabergoline therapy arrested the deterioration of symptoms. and decreased serum follicle-stimulating hormone concentrations. Cabergoline may be a useful treatment for aggressively growing non-prolactin-secreting pituitary adenomas.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9307745      PMCID： PMC2431370          DOI： 10.1136/pgmj.73.862.507

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  10 in total

Review 1.  Medical treatment of pituitary adenomas: effects on tumor growth.

Authors:  A Liuzzi; P G Chiodini; D Dallabonzana; G Oppizzi; G G Verde
Journal:  J Endocrinol Invest       Date:  1985-06       Impact factor: 4.256

2.  Effectiveness of cabergoline in reducing follicle-stimulating hormone and prolactin hypersecretion from pituitary macroadenoma in an infertile woman.

Authors:  A M Paoletti; G F Depau; V Mais; S Guerriero; S Ajossa; G B Melis
Journal:  Fertil Steril       Date:  1994-10       Impact factor: 7.329

3.  Bromocriptine therapy for non-functioning pituitary adenoma.

Authors:  D van Schaardenburg; F Roelfsema; A P van Seters; G J Vielvoye
Journal:  Clin Endocrinol (Oxf)       Date:  1989-05       Impact factor: 3.478

4.  Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine.

Authors:  J S Bevan; C W Burke
Journal:  Clin Endocrinol (Oxf)       Date:  1986-11       Impact factor: 3.478

5.  Reduction of follicle-stimulating hormone (FSH) secretion in FSH-producing pituitary adenoma by bromocriptine.

Authors:  M Berezin; D Olchovsky; A Pines; R Tadmor; B Lunenfeld
Journal:  J Clin Endocrinol Metab       Date:  1984-12       Impact factor: 5.958

6.  Acute effects of Parlodel-LAR and response to long-term treatment with bromocriptine in a patient with a follicle stimulating hormone-secreting pituitary adenoma.

Authors:  R Abs; P M Parizel; A Beckers
Journal:  J Endocrinol Invest       Date:  1991-02       Impact factor: 4.256

7.  Follicle-stimulating hormone- and alpha-subunit-secreting pituitary tumor treated with bromocriptine.

Authors:  M L Vance; E C Ridgway; M O Thorner
Journal:  J Clin Endocrinol Metab       Date:  1985-09       Impact factor: 5.958

8.  Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors.

Authors:  D L Barrow; G T Tindall; K Kovacs; M O Thorner; E Horvath; J C Hoffman
Journal:  J Neurosurg       Date:  1984-01       Impact factor: 5.115

9.  Long-term treatment with the dopamine agonist CV 205-502 of patients with a clinically non-functioning, gonadotroph, or alpha-subunit secreting pituitary adenoma.

Authors:  D J Kwekkeboom; S W Lamberts
Journal:  Clin Endocrinol (Oxf)       Date:  1992-02       Impact factor: 3.478

10.  The effect of dopamine agonist therapy on large functionless pituitary tumours.

Authors:  A Grossman; R Ross; M Charlesworth; C B Adams; J A Wass; I Doniach; G M Besser
Journal:  Clin Endocrinol (Oxf)       Date:  1985-05       Impact factor: 3.478
  10 in total
  1 in total

1.  Cabergoline modulation of alpha-subunits and FSH secretion in a gonadotroph adenoma.

Authors:  M Giusti; L Bocca; T Florio; L Foppiani; A Corsaro; L Auriati; R Spaziante; G Schettini; G Giordano
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.